BMS melanoma drug Opdivo wins priority review, breakthrough
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb got a double win from the FDA on 26 September, revealing the firm's biologic license application (BLA) for Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, was granted a priority as a therapy for patients previously treated for advanced melanoma.